Log In
Print this Print this

ProstVac, rilimogene galvacirepvec

Also known as: ProstVac-VF

  Manage Alerts
Collapse Summary General Information
Company Bavarian Nordic A/S
DescriptionVaccine targeting PSA that also contains a Tricom triad of costimulatory molecules -- CD58 (LFA-3), intercellular adhesion molecule-1 (ICAM-1; CD54) and CD80 (B7-1)
Molecular Target Prostate-specific antigen (KLK3) (PSA)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat androgen-independent castration-resistant prostate cancer (CRPC); Treat castration-resistant prostate cancer (CRPC) with bone metastases; Treat hormone-dependent prostate cancer; Treat localized prostate cancer; Treat metastatic castration-resistant prostate cancer (CRPC); Treat metastatic prostate cancer; Treat non-metastatic castration-sensitive prostate cancer; Treat prostate cancer; Treat prostate cancer in hormone-naïve patients
Regulatory Designation U.S. - Fast Track (Treat metastatic castration-resistant prostate cancer (CRPC));
U.S. - Special Protocol Assessment (Treat metastatic castration-resistant prostate cancer (CRPC))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today